| Serial Number | 98806913 |
| Word Mark | FAYUVI |
| Filing Date | Thursday, October 17, 2024 |
| Status | 688 - NOTICE OF ALLOWANCE - ISSUED |
| Status Date | Tuesday, July 1, 2025 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, May 6, 2025 |
| Goods and Services | Pharmaceutical, scientific, and medical research and development in the field of genetic, central nervous system, and lysosomal storage diseases and disorders; scientific research in the nature of conducting clinical trials for others in the field of genetic, central nervous system, and lysosomal storage diseases and disorders; scientific and medical research, namely, compiling and sharing of patient data for research purposes in the field of genetic, central nervous system, and lysosomal storage diseases and disorders; providing medical and scientific research information in the field of genetic, central nervous system, and lysosomal storage diseases and disorders; providing medical research and scientific research information in the field of genetic, central nervous system, and lysosomal storage diseases and disorders; pharmaceutical, scientific, and medical research and development in the field of gene therapy manufacturing technology; biomedical and scientific research in the fields of gene therapy, genetic, central nervous system, and lysosomal storage diseases and disorders; biomedical research in the field of gene therapy design and delivery; product development in the fields of genetic therapies and effectors to regulate, modulate, and characterize disease states; pharmaceutical research and development in the field of gene therapy; scientific research in the nature of conducting clinical trials for others in the field of gene therapy design and delivery |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, October 17, 2024 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Ultragenyx Pharmaceutical Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Novato, CA 94949 |
| Party Name | Ultragenyx Pharmaceutical Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Novato, CA 94949 |
| Event Date | Event Description |
| Thursday, October 17, 2024 | NEW APPLICATION ENTERED |
| Thursday, October 17, 2024 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Monday, March 24, 2025 | ASSIGNED TO EXAMINER |
| Tuesday, March 25, 2025 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Tuesday, March 25, 2025 | NON-FINAL ACTION E-MAILED |
| Monday, March 31, 2025 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, March 31, 2025 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Monday, March 31, 2025 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Saturday, April 5, 2025 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, April 30, 2025 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, May 6, 2025 | PUBLISHED FOR OPPOSITION |
| Tuesday, May 6, 2025 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, July 1, 2025 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Tuesday, March 25, 2025 | NON-FINAL ACTION WRITTEN |